Allotrap 2702

Drug Profile

Allotrap 2702

Alternative Names: 2702.75-84; Allotrap TM2702; HLA B2702

Latest Information Update: 07 Feb 2001

Price : $50

At a glance

  • Originator Stanford University Medical Center
  • Class Peptides
  • Mechanism of Action Cytotoxic T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Renal transplant rejection

Most Recent Events

  • 07 Feb 2001 Discontinued-II for Renal transplant rejection in France (IV-infusion)
  • 30 Apr 1998 A study has been added to the Transplant rejection pharmacodynamics section
  • 30 Jun 1997 A study has been added to the adverse events, pharmacokinetic and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top